TACSTD2 and small cell lung carcinoma: In 2017, the anti‐TROP2 ADC sacituzumab govitecan, which carries SN‐38 (a topoisomerase I inhibitor similar with topotecan, a second‐line treatment), showed promising therapeutic effects in advanced SCLC.153